Scarica l'app Stockscreener
2.99
9.93%
0.27
Dopo l'orario di chiusura:
2.90
-0.09
-3.01%
Connect Biopharma Holdings Ltd Borsa (CNTB) Ultime notizie
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Director at Connect Biopharma (CNTB) takes shares instead of cash pay - Stock Titan
[Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares - MarketBeat
CNTB Stock Price, Quote & Chart | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
Entity tied to CNTB director James Huang buys 1.16M shares in open market - Stock Titan
Connect Biopharma (NASDAQ: CNTB) holder Panacea adds 1.16M shares - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView
Connect Biopharma Holdings Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - The Manila Times
Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy - Stock Titan
[8-K] Connect Biopharma Holdings Ltd Reports Material Event - Stock Titan
New asthma and COPD drug data arrive as Connect funds operations into 2027 - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Receives "Buy" Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating on Connect Biopharma Hldgs (CNTB) | C - GuruFocus
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data - Investing.com Australia
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data By Investing.com - Investing.com South Africa
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Green Bay Press-Gazette
Connect Biopharma Announces Positive Phase 1 Results for IV Rademikibart, Showing Rapid Lung Function Improvement in Asthma and COPD Patients - minichart.com.sg
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses - MarketBeat
Connect Biopharma reports positive Phase 1 data for asthma drug By Investing.com - au.investing.com
Connect Biopharma raises $20.2 million in private placement By Investing.com - au.investing.com
Connect Biopharma stock jumps on positive drug trial results By Investing.com - Investing.com India
Connect Biopharma Announces $20.2 Million Private Placement Financing - Bitget
Connect Biopharma raises $20.2 million in private placement - Investing.com
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - Bitget
Connect Biopharma Raises $20.2 Million in Private Placement of 6.13 Million Shares at $3.25 - TradingView
Connect Biopharma reports positive Phase 1 data for asthma drug - Investing.com
Connect Biopharma (NASDAQ: CNTB) nets $20.2M and reports promising rademikibart results - Stock Titan
Connect Biopharma raises $20.2M, extends cash runway into 2027 - Stock Titan
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - globenewswire.com
A 2-minute IV shot improved breathing fast in asthma and COPD - Stock Titan
Connect Biopharma (CNTB) Expected to Announce Earnings on Monday - MarketBeat
CNTB SEC FilingsConnect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
If You Invested $1,000 in Connect Biopharma Holdings Ltd (CNTB) - Stock Titan
CONNECT BIOPHARMA HOLDINGS L (CNTB) Earnings History & Surprises - ChartMill
Connect Biopharma (CNTB) director linked fund reports 12M-share holding - Stock Titan
Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight – Company AnnouncementFT.com - Financial Times
[Form 3] Connect Biopharma Holdings Ltd Initial Statement of Beneficial Ownership - Stock Titan
Connect Biopharma (CNTB) president discloses share and option holdings - Stock Titan
Connect Biopharma (CNTB) CEO details stock option and share holdings - Stock Titan
Connect Biopharma (CNTB) SVP lists Ordinary Shares and option grants - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial share and option holdings - Stock Titan
Connect Biopharma (CNTB) director lists stock option and share stakes - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial stock option holdings - Stock Titan
Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts - MarketBeat
CNTB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Severe Asthma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma - StreetInsider
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):